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Abstract
Introduction Mammographic breast density is one of the
strongest known risk factors for breast cancer. We present a
novel technique for estimating breast density based on 3D T1-
weighted Magnetic Resonance Imaging (MRI) and evaluate its
performance, including for breast cancer risk prediction, relative
to two standard mammographic density-estimation methods.
Methods The analyses were based on MRI (n = 655) and
mammography (n = 607) images obtained in the course of the
UK multicentre magnetic resonance imaging breast screening
(MARIBS) study of asymptomatic women aged 31 to 49 years
who were at high genetic risk of breast cancer. The MRI percent
and absolute dense volumes were estimated using our novel
algorithm (MRIBview) while mammographic percent and
absolute dense area were estimated using the Cumulus
thresholding algorithm and also using a 21-point Visual
Assessment scale for one medio-lateral oblique image per
woman. We assessed the relationships of the MRI and
mammographic measures to one another, to standard
anthropometric and hormonal factors, to BRCA1/2 genetic
status, and to breast cancer risk (60 cases) using linear and
Poisson regression.
Results MRI percent dense volume is well correlated with
mammographic percent dense area (R = 0.76) but overall gives
estimates 8.1 percentage points lower (P < 0.0001). Both show
strong associations with established anthropometric and
hormonal factors. Mammographic percent dense area, and to a
lesser extent MRI percent dense volume were lower in BRCA1
carriers (P = 0.001, P = 0.010 respectively) but there was no
association with BRCA2 carrier status. The study was
underpowered to detect expected associations between
percent density and breast cancer, but women with absolute
MRI dense volume in the upper half of the distribution had
double the risk of those in the lower half (P = 0.009).
Conclusions The MRIBview estimates of volumetric breast
density are highly correlated with mammographic dense area
but are not equivalent measures; the MRI absolute dense
volume shows potential as a predictor of breast cancer risk that
merits further investigation.
BMI: body mass index; CC: cranio-caudal; CI: confidence interval; IQR: inter quartile range; IRR: incidence rate ratio; MARIBS: magnetic resonance 
imaging breast screening; MLO: medial-lateral oblique; MLPA: multiple ligation dependant probe amplification; MRI: magnetic resonance imaging; 
ONS: office of national statistics; RR: relative risk; UCL: University College London; VA: visual assessment; WHR: waist-hip ratio; XRM: X-ray mam-
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Introduction
Mammographic breast density is usually defined as the pro-
portion of a mammographic image occupied by radiodense tis-
sue (largely stromal and epithelial tissues, appearing as white
regions) as opposed to nondense, fatty tissue (the darker
regions of the image). Thus defined, a high degree of mammo-
graphic density is one of the strongest known risk factors for
breast cancer. A recent meta-analysis of 42 studies reported
an almost five-fold increase in risk between the most dense
and least dense groups of women [1]. The association
between high density and risk is also believed to be present in
women who are already at an elevated risk of breast cancer as
a result of carrying a mutation in the BRCA1 or BRCA2 genes
[2]. While continuous, quantitative measures of breast density
provide more accurate predictions of breast cancer risk than
the older qualitative measures (e.g. BIRADS or Wolfe scoring
systems) [1], it is still not clear that optimal relevant information
can be obtained from a two-dimensional mammographic
image.
Using data from the UK MARIBS (magnetic resonance imag-
ing in breast screening) study, we have developed a novel
technique based on three-dimensional T1-weighted Magnetic
Resonance Imaging (MRI) for obtaining estimates of the abso-
lute and proportional volumes of the breast occupied by dense
tissue [3]. The MRI density differs from that obtained from
mammography in that it is based on a three-dimensional image
of the breast and differentiates between dense and non-dense
tissue on the basis of behaviour in response to a magnetic field
rather than to x-ray radiation. We considered both the absolute
volume occupied by dense material, and the dense volume as
a proportion of the entire breast volume.
In the absence of an established biological gold-standard
measure of the quantity of dense tissue in the breast, we eval-
uated the performance of our MRI-based method via direct
comparison with two mammography-based methods and by
assessing correlations with known anthropometric and hormo-
nal determinants of breast density. We also looked at the rela-
tionships between MRI and mammographic breast density
measures and BRCA1/2 genetic status, and attempted to
assess their relative usefulness for breast cancer risk predic-
tion.
The MARIBS study was restricted to carriers of BRCA1,
BRCA2 or TP53 mutations, their relatives and other women
believed to be at high genetic risk of breast cancer. Hence the
results of this study relate to the group of women in whom
breast MRI for breast screening is most likely to take place,
and therefore for whom MRI-based density estimation is most
likely to be possible without the need for additional examina-
tions. In addition it has potential value as a radiation-free den-
sity-estimation technique suitable for use from a young age in
radiation-susceptible women.
Materials and methods
MARIBS study design
The study population was taken from women who participated
in the MARIBS study [4,5]., in which 837 asymptomatic
women aged 31 to 49 years thought to be at high genetic risk
of breast cancer (carriers of BRCA1, BRCA2 or TP53 muta-
tions, their first degree relatives, or untested women with a
strong family history of breast and/or ovarian cancer, or a fam-
ily history suggestive of Li-Fraumeni syndrome; estimated
annual risk of breast cancer ≥ 0.9%) consented, of whom 741
attended for MRI and/or X-ray mammography (XRM) in at least
one year. All MARIBS participants had given informed consent
to a protocol approved by the London Multicentre Research
Ethics Committee (reference no. MREC98/2/38) and had
specifically consented to their anonymised medical images
from the study being used for teaching and research pur-
poses.
Quantitative mammographic dense area estimation by 
interactive thresholding
After the close of the study the mammograms were requested
from the study centres and from other hospitals which pro-
vided routine mammography to study participants (23 hospi-
tals). The recall of mammograms provided a useable image for
607 women (contralateral side only for the 42 women who
developed breast cancer; a useable image was only available
for one side for a further 31 women). The 607 women included
33 who had consented to participate in the MARIBS study but
who had not attended for a study MRI or XRM examination; in
these cases the density estimation was based on mammo-
graphic images taken outside the context of the MARIBS
study. The multi-centre design of the study restricted our abil-
ity to trace mammograms from all the women, in part because
some centres routinely destroy mammograms after a certain
period. Original mammograms retrieved from the centres were
digitised using an Array 2905 DICOM ScanPro Plus Laser
Film Digitiser Version 1.3E (Array Corp., Hampton, NH, USA)
at optical density of 4.7.
The Medial-Lateral Oblique (MLO) images from each breast
were used for mammographic density assessment by the two-
dimensional interactive method developed by the University of
Toronto (CUMULUS V3.1) [6] This method estimates dense
breast area and whole breast area from scanned mammo-
grams and hence percentage density. The pectoral muscle is
excluded from the image before measuring. The craniocaudal
(CC) images were also read for the 481 women for which they
were available. RW read all images and also independently
second read 158 images for repeatability analyses. All images
were read as individual images blinded to all patient informa-
tion and all other readings.
Visual Assessment of mammographic dense area
Mammographic density was also assessed visually by an expe-
rienced radiologist (CB) for images from 599 women. The dig-Available online http://breast-cancer-research.com/content/11/6/R80
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itised MLO images were viewed individually on a standard PC
and a percentage estimate of density to 5% was made by the
radiologist using a 21-point scale. This method is designed to
detect differences smaller than one Boyd category. The crani-
ocaudal (CC) images were also read for the 456 women for
which they were available. CB read all the images and also
independently second read 93 images for repeatability analy-
ses.
MRI-based estimation of dense volume
Breast MRI images were obtained for 655 women. The
method of density measurement used was devised for this
analysis and a pilot study has been published previously [3]. In
brief, water-containing tissues were identified by interactive
segmentation of tissues anterior to the pectoral muscle on the
basis of signal intensity in the pre-contrast T1 weighted
images. A coil-uniformity correction based on the proton den-
sity image was applied prior to segmentation of water-based
and fat-based tissues. Percentage MRI density was calculated
as the ratio of the volume occupied by MRI water-containing
tissue to the total volume of breast tissue.
Only the contralateral side was considered for the 55 women
who developed breast cancer; two further women only had
readable images from one side. Wherever possible the density
reading was based on the first MRI study conducted in the
MARIBS study (n = 645), with the second year study being
used for the remaining 10 women. Two readers (EB and SR)
were trained to obtain consistent readings using this experi-
mental method. EB read the images for 196 women and SR
read those for the remaining 459 women. For repeatability
analyses SR independently second read images from 97 of
the women originally read by EB (left breasts only used in
repeatability analysis to avoid non-independence of the two
sides from the same woman).
In summary, the breast density was estimated using both
Cumulus and MRI for 513 women, with 142 women having
just a MRI density estimate and 94 having just a Cumulus esti-
mate, giving a total of 749 participants. Where more than one
mammogram could be traced we used that which was closest
in time to the used MRI study; in 423 cases (82.5%) the mam-
mogram was from the same screening round as the MRI
image, with a further 42 cases being one year apart (i.e. 90.6%
were no more than one year apart).
Breast cancers in the MARIBS study
Thirty-three screen detected and two interval breast cancers
were included in the original report of the MARIBS study in
2005 [5]. An additional four cancers occurred during the
study but were excluded from that analysis because they did
not have matched MRI and XRM screening episodes. Thirty-
eight of the 39 women with breast cancer have density esti-
mates for MRI and XRM (n = 25), for MRI only (n = 12) or for
XRM only (n = 1, who had declined an MRI examination), so
are eligible for this analysis. Mammograms could not be traced
for 12 cases, explaining the discrepancy in numbers.
Information on breast cancers diagnosed after the end of the
study was obtained via a follow up questionnaire sent to par-
ticipants in 2006 and by contacting each of the study centres.
Women were also flagged at the Office of National Statistics
(ONS) to ascertain subsequent cancer incidence and mortal-
ity (having given their written consent). Final follow up includ-
ing at least 52 months from the last MRI scan was censored
at 31 July 2007. We were thus made aware of 28 cancers
which emerged since the study closed, of which 22 were eli-
gible for this analysis (13 had MRI and XRM density estimates,
6 had MRI only and 3 had XRM only), giving a total of 60
cases.
This study therefore reflects a combination of prevalent
(detected at the time of the screening examination used in the
density-estimation, for which density estimates used only the
contra-lateral breast) and incident (diagnosed subsequent to
the screening examination used in the density estimation,
either during a subsequent screening round, or as an interval
or follow-up cancer) breast cancers. For the MRI density anal-
ysis there were 19 prevalent and 37 incident cancers; for the
Cumulus analysis the numbers were 15 and 27 respectively.
Genetic analyses in the MARIBS population
On the basis of clinical genetic testing independent of this
study we were aware of 94 BRCA1 and 55 BRCA2 mutation
carriers and 54 BRCA1/2 non-carriers among the 749
women. Fourteen women had undergone clinical genetic test-
ing for TP53 mutations (12 positive and 2 negative).
Throughout this report we use the term non-carrier to refer to
a woman who has tested negative for a specific mutation
known to be carried by an affected relative, whereas we
describe women as having an uninformative test result if no
mutations were detected by a general mutation screen.
Women whose genetic status was not known at recruitment,
including those with an uninformative test result, were invited
to provide a blood sample for later anonymous genetic testing.
Seven women were anonymously tested for mutations in the
TP53 gene and 339 were tested for BRCA1 and BRCA2
mutations by complete gene sequencing to identify coding
sequence mutations and by Multiple Ligation-Dependent
Probe Amplification (MLPA) to identify large genomic rear-
rangements and deletions, as previously described [7]. Vari-
ants of unknown significance not classed as clinically
important by the Breast Cancer Information Core [8] were
assumed to be non-deleterious.
Combining clinical test results with the results of our anony-
mous genotyping we identified 125 BRCA1 mutation carriers,
80 BRCA2 mutation carriers and 12 carriers of mutations in
the TP53 gene. One hundred and two women tested negativeBreast Cancer Research    Vol 11 No 6    Thompson et al.
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for a known family mutation (56 BRCA1, 41 BRCA2 and 5
TP53) [Table S1 in Additional data file 2].
The details of the remaining women are given in table S1 in
Additional data file 2. Pedigrees were available for 112 of the
women without any genetic testing and for 296 of the 303
with an uninformative BRCA1/2 test result (either clinical or
research). These were used to estimate each woman's proba-
bility of carrying a BRCA1 or BRCA2 mutation given her per-
sonal and family history of cancer and mutation testing, based
on the Boadicea computer program [9]. The sensitivity param-
eters for BRCA1 and BRCA2 mutation screening were set as
70% and 80% respectively. In summary, 70 women had not
been tested and had had no testing in their family (median
Boadicea carrier probability = 9.0% IQR (inter quartile range)
= 1.8 to 23.3%); 42 had not been tested but were related to
a tested BRCA1/2 mutation carrier (median Boadicea carrier
probability = 28.9% IQR = 22.8 to 31.9%) and the remaining
299 had been screened for BRCA1/2 mutations (or a relative
had) without a deleterious mutation having been detected.
Using clinical criteria this last group are considered as unin-
formative, although the thoroughness of the mutation screen-
ing suggests that they are unlikely to be missed mutation
carriers. This is supported by a median Boadicea probability of
not carrying a BRCA1 or BRCA2 mutation of 98.4% [IQR =
91.9 to 99.6%].
MARIBS questionnaire information
At the time of recruitment 576 of the 749 women (76.9%)
completed a questionnaire containing questions relating to
lifestyle risk factors, reproductive and hormonal history and
various standard anthropometric measures (Table 1 and Table
2).
Statistical analysis
The primary analyses were based on three measures of pro-
portional density (MRI percent dense volume, Cumulus-meas-
ured percent mammographic dense area and visually-
assessed percent mammographic percent dense area on a
21-point scale) and two measures of absolute density (MRI
dense volume and Cumulus mammographic dense area), as
described above. All analyses of mammographic density refer
to the MLO projection unless otherwise specified.
The relationships between the density measures for the left
and right breasts were assessed using Pearson linear correla-
tion coefficients and t-tests. The mean unsigned difference
between breasts (i.e. not taking into account which of a
woman's breasts is the denser) is also presented. The relation-
ship between the MRI percent dense volume and Cumulus
percent dense area was assessed using linear regression.
Correlation coefficients and weighted kappa statistics (assum-
ing equal spacing between the four quartiles derived on the
basis of the full dataset) were used to describe inter-reader
(MRI) and intra-reader (Cumulus and Visual Assessment (VA))
consistencies.
Linear regression was used to examine associations between
the density measures and a range of standard variables, with
the two MRI measures log-transformed to closer approximate
a normal distribution. Continuous variables were divided into
quartiles; age at study registration, weight, body mass index
(BMI, defined as weight in kg divided by the square of height
in metres), hip, waist and chest circumferences and waist:hip
ratio (WHR, defined as the ratio of the waist circumference to
the hip circumference). Parity was defined as the number of
full-term pregnancies; women with four or more were consid-
ered as a single group. The following binary variables were
also considered: current/previous smokers vs never smokers;
women who had ever been pregnant vs  never pregnant;
women who had ever used hormone replacement therapy vs
those who had not; women who had previously taken an oral
contraceptive vs those who had not; women who had ever
taken tamoxifen as part of a prevention trial vs those who had
not. Women who reported that their menstrual periods had
stopped due either to a natural menopause, a hysterectomy or
an oophorectomy were considered as being postmenopausal.
The mean values of each density measure for the BRCA1/2
genetic groups were adjusted for age at registration ≥ 45
years and associations between genetic status and density
were tested using linear regression. The analyses were
repeated additionally adjusting for BMI and parity.
Finally, Poisson regression was used to test whether each of
the density measures was associated with cancer risk in this
population by quartile of density, and also grouping the two
lower and two upper quartiles in order to improve the stability
of the estimates. Each individual's at-risk period was defined
as starting at their study registration and continuing until the
earliest of breast cancer diagnosis, death, prophylactic bilat-
eral mastectomy, other loss to the ONS flagging system or 31
July 2007. The analyses were performed adjusting only for age
group, adjusting for genetic status and/or BMI and parity, and
also separately for BRCA1 mutation carriers, BRCA2 muta-
tion carriers and uninformative/non-carriers. The power to
detect a doubling of risk between the upper and lower halves
of the density distribution was 72% for the MRI percent dense
volume and 59% for the Cumulus percent dense area, rising
to 92% and 82% for a 2.5-fold increase in risk.
All statistical tests are two-sided and were conducted using
Stata version 10.0 (StataCorp, 4905 Lakeway Drive, College
Station, Texas 77845, USA).
Results
It was possible to estimate the MRI breast dense volume for
655 of the women, while suitable mammograms were
obtained and read using the Cumulus density-estimation pro-Available online http://breast-cancer-research.com/content/11/6/R80
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Table 1
Relationship between measures of breast density and eight continuous variables, by quartile
Quartile 2 Quartile 3 Quartile 4
NP trend Phet Coefficient
(95% CI)
Coefficient
(95% CI)
Coefficient
(95% CI)
MRI % dense volume (log)
age 655 < 0.001 < 0.001 -0.02 (-0.14, 0.11) -0.08 (-0.22, 0.06) -0.38 (-0.52, -0.25)
weight 519 < 0.001 < 0.001 -0.29 (-0.42, -0.16) -0.43 (-0.56, -0.29) -0.83 (-0.97, -0.70)
BMI 517 < 0.001 < 0.001 -0.22 (-0.35, -0.09) -0.48 (-0.61, -0.35) -0.86 (-0.99, -0.72)
hip 429 < 0.001 < 0.001 -0.17 (-0.31, -0.03) -0.29 (-0.45, -0.12) -0.68 (-0.84, -0.53)
Waist 438 < 0.001 < 0.001 -0.10 (-0.25, 0.06) -0.29 (-0.43, -0.14) -0.65 (-0.81, -0.49)
Chest 449 < 0.001 < 0.001 -0.22 (-0.36, -0.09) -0.37 (-0.52, -0.22) -0.86 (-1.01, -0.70)
WHR 427 0.006 0.032 -0.09 (-0.26, 0.08) -0.09 (-0.26, 0.08) -0.26 (-0.43, -0.09)
Parity 633 0.008 0.052 -0.19 (-0.36, -0.01) -0.19 (-0.33, -0.05) -0.22 (-0.39, -0.05)
Cumulus % dense area
age 607 0.003 0.004 -1.58 (-5.87, 2.71) -0.53 (-5.20, 4.14) -7.66 (-12.2, -3.08)
weight 464 < 0.001 < 0.001 -9.21 (-13.7, -4.72) -17.2 (-21.7, -12.7) -26.6 (-31.0, -22.1)
BMI 462 < 0.001 < 0.001 -7.97 (-12.4, -3.56) -15.7 (-20.1, -11.3) -27.6 (-32.0, -23.3)
hip 378 < 0.001 < 0.001 -5.59 (-10.4, -0.78) -10.7 (-16.3, -5.10) -24.4 (-29.3, -19.6)
Waist 386 < 0.001 < 0.001 -3.56 (-8.99, 1.86) -11.3 (-16.2, -6.47) -20.9 (-26.0, -15.8)
Chest 397 < 0.001 < 0.001 -9.73 (-14.2, -5.28) -13.9 (-18.9, -8.89) -29.6 (-34.7, -24.6)
WHR 375 0.003 0.005 -6.14 (-11.8, -0.49) -3.18 (-8.95, 2.59) -10.1 (-15.9, -4.41)
Parity 596 < 0.001 0.002 -5.70 (-11.2, -0.20) -5.82 (-10.4, -1.26) -8.70 (-14.1, -3.27)
Visually Assessed % dense area
age 599 0.001 0.004 -1.69 (-6.13, 2.75) -1.71 (-6.52, 3.10) -8.34 (-13.1, -3.60)
weight 458 < 0.001 < 0.001 -6.87 (-11.7, -2.05) -14.1 (-18.9, -9.29) -24.8 (-29.5, -20.0)
BMI 456 < 0.001 < 0.001 -6.22 (-11.0, -1.46) -12.5 (-17.2, -7.70) -26.0 (-30.6, -21.3)
hip 374 < 0.001 < 0.001 -4.29 (-9.33, 0.76) -8.80 (-14.7, -2.94) -23.6 (-28.6, -18.5)
Waist 382 < 0.001 < 0.001 -3.21 (-8.91, 2.49) -9.63 (-14.7, -4.53) -21.1 (-26.4, -15.7)
Chest 391 < 0.001 < 0.001 -9.64 (-14.3, -4.93) -13.3 (-18.6, -8.00) -29.5 (-34.8, -24.2)
WHR 371 0.007 0.01 -5.51 (-11.4, 0.36) -2.31 (-8.32, 3.71) -9.81 (-15.8, -3.83)
Parity 588 < 0.001 < 0.001 -5.66 (-11.3, -0.05) -6.41 (-11.1, -1.75) -10.8 (-16.4, -5.31)
Quartile 2 Quartile 3 Quartile 4
NP trend Phet Coefficient
(95% CI)
Coefficient
(95% CI)
Coefficient
(95% CI)
MRI dense volume (×103, log)
age 651 0.24 0.57 -0.05 (-0.18, 0.08) -0.03 (-0.17, 0.12) -0.10 (-0.25, 0.04)
weight 515 0.12 0.38 0.07 (-0.09, 0.23) 0.13 (-0.03, 0.29) 0.11 (-0.05, 0.28)
BMI 513 0.75 0.47 0.10 (-0.05, 0.26) 0.10 (-0.06, 0.26) 0.02 (-0.14, 0.19)
hip 425 0.072 0.13 0.12 (-0.04, 0.29) 0.21 (0.02, 0.40) 0.13 (-0.04, 0.31)Breast Cancer Research    Vol 11 No 6    Thompson et al.
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gram for 607 women, all but eight of whom were also
assessed on the 21-point Visual Assessment (VA) score. For
all techniques there was strong concordance between the
percentage densities of the left and right breasts with neither
side being consistently denser than the other (P = 1.0 for MRI,
P = 0.32 for Cumulus, P = 0.31 for VA) [Additional data file
3]. Where both sides were available, the analyses were based
on the mean density over both sides [Table S2 in Additional
data file 2]; note that no MRI image was recorded as having
zero dense volume.
The percent dense volume measured by MRI was positively
correlated with the percent dense area estimated using the
Cumulus program (Figure 1, correlation coefficient = 0.76),
but was on average 8.1 percentage points lower (95% CI 7.0
to 9.3, P < 0.0001). The relationship between these measures
appears to be non-linear. There was a steeper slope for the
denser breasts [slope = 0.64 (0.53 to 0.74, P < 0.001) for
women with a Cumulus dense area ≥ 30%], compared with
women with a Cumulus-density < 30% [slope = 0.43 (0.32 to
0.54, P < 0.001)] (P = 0.0036 for the difference between the
two slopes). The 30% cut-off was based on visual inspection
of the scatter-plot. On average the MRI percent dense volume
was 14.9 percentage points lower (95% CI 13.5 to 16.4) than
the Cumulus percent dense area (P < 0.0001) for the women
with mammographically denser breasts, but there was no sig-
nificant difference for the less dense breasts (P  = 0.20).
Despite the strong correlation there were a few women for
whom the MRI and Cumulus estimates were highly divergent.
The correlation between the MRI absolute dense volume and
the Cumulus absolute dense area was clearly present but was
weaker than for the corresponding percent densities (R =
0.61) [Additional data file 4].
The MRI percent dense volume estimates were highly consist-
ent between the two readers for the 97 images read by both,
with a correlation coefficient of 0.94 and a weighted inter-
reader kappa of 0.74 based on the quartiles. The Cumulus and
VA mammographic percent dense areas were each read by a
single reader; 158 images were independently read twice by
the Cumulus reader and 93 images were independently read
twice by the VA reader. The intra-reader correlation coeffi-
cients were 0.90 and 0.92 respectively and weighted kappa
coefficients of 0.72 and 0.73 respectively.
The relationships between breast density and a series of
standard anthropometric and reproductive/hormone-related
factors were assessed for the MRI and mammographic density
measures (percent and absolute dense areas and volumes), in
order to establish whether the relationships seen in unse-
lected populations are also true in this high-risk group of
women, and to see whether breast density as measured by our
novel MRI-density estimation technique is related to the same
factors as mammographic breast density (Tables 1 and 2).
The Cumulus percent dense area was negatively associated
with BMI, weight, hip, waist and chest circumferences and
with parity (trend P < 0.001 in each case) and with WHR (P
= 0.003), as expected. Although there was a significant nega-
tive trend in Cumulus percent density with increasing age, a
significant decrease was seen only for women in the oldest
age quartile (≥ 45 years; P  = 0.001). Post-menopausal
women, women who had ever been pregnant and women who
Waist 434 0.063 0.19 -0.03 (-0.21, 0.15) 0.12 (-0.04, 0.28) 0.13 (-0.05, 0.31)
Chest 445 0.021 0.034 0.07 (-0.09, 0.22) 0.25 (0.08, 0.42) 0.15 (-0.04, 0.33)
WHR 423 0.25 0.64 0.00 (-0.18, 0.18) 0.08 (-0.10, 0.26) 0.09 (-0.10, 0.27)
Parity 629 0.14 0.46 -0.13 (-0.31, 0.05) -0.10 (-0.25, 0.04) -0.11 (-0.29, 0.06)
Cumulus dense volume (×103)
age 607 0.35 0.21 -187 (-433, 59.0) 15.1 (-252, 283) -201 (-464, 61.9)
weight 464 0.003 0.017 9.71 (-267, 286) -233 (-509, 43.4) -366 (-641, -92.1)
BMI 462 0.001 0.004 52.7 (-223, 328) -150 (-426, 127) -419 (-690, -148)
hip 378 < 0.001 < 0.001 95.6 (-181, 372) 47.4 (-274, 369) -545 (-824, -266)
Waist 386 0.027 0.14 -12.2 (-322, 298) -135 (-414, 143) -323 (-613, -31.9)
Chest 397 0.003 < 0.001 77.1 (-187, 341) 79.5 (-219, 378) -516 (-817, -216)
WHR 375 0.99 0.55 -83.7 (-387, 219) 122 (-187, 432) -67.6 (-375, 240)
Parity 596 0.001 0.012 -287 (-601, 26.6) -285 (-545, -25.1) -447 (-756, -137)
N = number of women for whom data were available. Ptrend and Phet are P-values for the tests of trend (1 df) and heterogeneity (3 df) respectively 
between quartiles. Coefficients are for each quartile of the variable relative to the lowest quartile.
Table 1 (Continued)
Relationship between measures of breast density and eight continuous variables, by quartileAvailable online http://breast-cancer-research.com/content/11/6/R80
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Table 2
Relationship between measures of breast density and six binary variables
No. 'Yes' No. 'No' coefficient (95% CI) P-value
MRI % dense volume (log)
Ever smoker 229 304 -0.01 (-0.12, 0.10) 0.82
Post-menopausal 108 418 -0.32 (-0.45, -0.19) < 0.001
Ever pregnant 466 64 -0.22 (-0.39, -0.06) 0.008
Ever tamoxifen use 28 506 -0.44 (-0.67, -0.20) < 0.001
Previous OC use 426 106 -0.16 (-0.29, -0.02) 0.023
Ever HRT use 17 97 0.01 (-0.32, 0.33) 0.98
Cumulus %dense area
Ever smoker 206 270 0.21 (-3.43, 3.86) 0.91
Post-menopausal 101 372 -8.95 (-13.3, -4.60) < 0.001
Ever pregnant 424 49 -7.10 (-13.0, -1.18) 0.019
Ever tamoxifen use 30 447 -10.4 (-17.8, -3.07) 0.006
Previous OC use 379 96 0.35 (-4.15, 4.86) 0.88
Ever HRT use 12 73 1.11 (-11.2, 13.4) 0.86
Visually Assessed % dense area
Ever smoker 202 268 -1.25 (-5.05, 2.56) 0.52
Post-menopausal 101 366 -10.3 (-14.8, -5.75) < 0.001
Ever pregnant 418 49 -8.16 (-14.3, -2.03) 0.009
Ever tamoxifen use 29 442 -13.0 (-20.8, -5.28) 0.001
Previous OC use 374 95 -0.39 (-5.08, 4.31) 0.87
Ever HRT use 11 71 5.34 (-7.16, 17.8) 0.41
MRI dense volume (×103, log)
Ever smoker 226 303 0.05 (-0.07, 0.16) 0.43
Post-menopausal 107 415 -0.05 (-0.19, 0.09) 0.50
Ever pregnant 463 63 -0.17 (-0.34, 0.00) 0.05
Ever tamoxifen use 28 502 -0.07 (-0.32, 0.18) 0.60
Previous OC use 423 106 -0.08 (-0.22, 0.06) 0.24
Ever HRT use 17 97 0.12 (-0.24, 0.47) 0.52
Cumulus dense area (×103)
Ever smoker 206 270 41.9 (-156, 240) 0.68
Post-menopausal 101 372 -251 (-491, -10.6) 0.041
Ever pregnant 424 49 -273 (-596, 49.7) 0.098
Ever tamoxifen use 30 447 -273 (-677, 131) 0.19
Previous OC use 379 96 56.1 (-189, 301) 0.65
Ever HRT use 12 73 180 (-419, 778) 0.56Breast Cancer Research    Vol 11 No 6    Thompson et al.
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had ever used tamoxifen also had lower percent dense areas
(P < 0.001, P = 0.019 and P = 0.006 respectively).
Lower MRI percent dense volume was significantly associated
with all of the same variables, and additionally showed a pos-
sible negative association with previous oral contraceptive use
(P = 0.023).
The Cumulus measure of absolute dense area was signifi-
cantly associated with the same variables as the Cumulus per-
cent density, apart from age, tamoxifen use and ever-
pregnancy, but the associations were in each case less signif-
icant than for percent dense area. The MRI measure of abso-
lute dense volume showed a modestly significant association
with chest circumference (P = 0.021) but not with any of the
other tested variables.
The results of the univariate analyses were used as the starting
point for multivariate analyses. For the Cumulus and MRI per-
cent density measures, the best fitting models both consisted
of terms for age ≥ 45 years, parity, BMI (trend by quartiles) and
chest circumference (trend by quartiles). However, chest cir-
cumference was only available for 491 women and so, to avoid
excessive reduction in sample sizes, subsequent analyses
were conducted under two models: 1) adjusted for age ≥ 45
years only; 2) adjusted for age ≥ 45 years, BMI quartiles and
parity.
Breast density measures and BRCA1/BRCA2 genotype
Figures 2 and 3 show the means of the age-adjusted percent
and absolute breast density measures according to BRCA1/
BRCA2 genotype. TP53 carriers and others with a Li-Frau-
meni syndrome family history were not included in this part of
the analysis because of their small numbers. For each of the
percent and absolute density measures, women with an unin-
formative genetic test (the baseline group) tended to have
denser breasts than either the BRCA1 or BRCA2 carriers or
non-carriers. The comparison with non-carriers was only signif-
icant for the MRI percent density, and then only when BRCA1
and BRCA2 non-carriers were combined (P = 0.015 adjusted
only for age ≥ 45; P = 0.049 adjusted for age ≥ 45, BMI and
parity).
BRCA1 mutation carriers had significantly lower MRI percent
dense volume (P = 0.010), Cumulus percent dense area (P =
0.001), VA percent dense area (P  < 0.001) and Cumulus
absolute dense volume (P = 0.002) than the uninformative
group; these effects remained significant after adjustment for
BMI and parity (Figures 2 and 3), but their MRI absolute dense
volume was no different from that of the uninformative group
(P = 0.46, Figure 3). BRCA2 mutation carriers did not differ
from the uninformatives for any density measures except
Cumulus absolute dense area (P = 0.021), and this result was
non-significant after adjustment for BMI and parity (P = 0.31).
The data were reanalysed in terms of the Boadicea-estimated
BRCA1 and BRCA2 carrier probabilities (tested carriers and
non-carriers were assumed to have probabilities of 1 or 0, as
appropriate) using multivariate regression. BRCA1  carrier
probability was negatively associated with Cumulus percent
density (P = 0.001, P = 0.016 after adjustment for BMI and
parity) but not with MRI percent dense volume (P = 0.047, P
= 0.066 adjusted). BRCA2 carrier probability was not associ-
ated with MRI or Cumulus percent densities (P = 0.95 and P
= 0.24 respectively, age adjusted).
Breast density measures and risk of breast cancer
Thirty-eight of the 749 women developed breast cancer during
the course of the MARIBS study; a further 22 developed
breast cancer between their last MARIBS screening round
and the cut-off date of 31/07/2007. Unfortunately we were
unable to obtain any mammogram for 12 of the women with a
breast cancer during the study, so the comparison of the MRI
and Cumulus/Visual density measures are not based on equal
numbers.
Breast cancer incidence rate showed no significant associa-
tions with MRI percent dense volume or Cumulus/Visual per-
cent dense area, except when the analyses were adjusted for
BRCA1 and BRCA2 genotype/carrier probability (Upper two
quartiles vs lower two quartiles: IRR (incidence rate ratio) =
2.04 (1.16 to 3.59) P = 0.013 for MRI; IRR = 2.24 (1.18 to
4.26) P = 0.014 for VA). These incidence rate ratios ceased
Figure 1
Relationship between MRI percentage dense volume and Cumulus per- centage dense area (n = 509) Relationship between MRI percentage dense volume and Cumulus per-
centage dense area (n = 509). The least-squares best-fit lines for 
women with cumulus percent dense areas < 30% and ≥ 30% are 
shown in grey.Available online http://breast-cancer-research.com/content/11/6/R80
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to be significant when further adjusted for parity and BMI,
although this may be due to the smaller numbers of women for
whom these data were available (Table 3). Stratifying by gen-
otype did not reveal any convincing specific associations
between breast cancer incidence and either percent dense
area or volume, although the numbers of cancers in each
group were small (Table 4). Use of the craniocaudal mammo-
graphic view instead of or in addition to the mediolateral
oblique view did not appear to improve the predictive value of
the Cumulus or Visual percent dense area in this population
[Table S3 in Additional data file 2].
The Cumulus absolute dense area showed no evidence of
association with breast cancer incidence (Tables 5 and 6).
However, the MRI absolute dense area was associated with
an approximately two-fold increase in risk between the higher
and lower halves of the distribution, even after adjustment for
age ≥ 45, BMI, parity and BRCA1/BRCA2 carrier status/prob-
ability (IRR = 2.16 (1.12 to 4.17) P = 0.021; IRR = 1.35 (1.01
to 1.80) P = 0.042 for trend in quartiles) (Table 5). The asso-
ciation appeared to be broadly similar in BRCA1 and BRCA2
carriers (BRCA1  IRR = 3.62 (1.32 to 9.90) P  = 0.012;
BRCA2 IRR = 3.06 (1.14 to 8.19) P = 0.026) but was not
Figure 2
Age-adjusted means and 95% confidence intervals for MRI percent dense volume, Cumulus percent dense area and visual assessment percent  dense area by BRCA1/BRCA2 genetic status Age-adjusted means and 95% confidence intervals for MRI percent dense volume, Cumulus percent dense area and visual assessment percent 
dense area by BRCA1/BRCA2 genetic status. P-values are for the comparisons with the group of women with uninformative BRCA1/2 genetic test 
results, as assessed by linear regression (P-values further adjusted for BMI and parity are given in parentheses). Arithmetic means are presented for 
the Cumulus and Visual measurements; geometric means are shown for the MRI measure (for which the regression analyses were based on log-
transformed values). Box areas are proportional to sample size.Breast Cancer Research    Vol 11 No 6    Thompson et al.
Page 10 of 16
(page number not for citation purposes)
apparent in the non-carriers/uninformative women (P = 0.66)
(Table 6).
Discussion
We present the results of a large multicentre study designed
to explore the value of a novel MRI-based technique for esti-
mating breast density, specifically in a group of women at high
genetic risk of breast cancer.
The proportion of the breast volume occupied by dense mate-
rial, as measured using our MRI-based algorithm, was strongly
correlated with the proportion of the mammographic breast
area occupied by dense material, as measured by the quanti-
tative Cumulus thresholding algorithm. Previous studies of
considerably fewer women have reported broadly similar cor-
relations between various MRI-based and mammography-
based density estimates for example [3,10-12]. However, cor-
relation is not the same as equivalence, and it seems that a
woman's MRI percent dense volume tends to be lower (on
average by eight percentage points) than her Cumulus per-
cent dense area, with a more marked difference among
women with denser breasts. The proportional densities esti-
mated by the two methods were notably different for a small
number of women; in some cases this may have been due to
the use of a later mammogram if an image from the same year
as the corresponding MRI was not available, otherwise it may
simply reflect the occasional fallibility of human-operated
methods.
Mammography separates fatty tissue from tissues of water
density on the basis of their differential absorption of the X-ray
beam, whereas MRI distinguishes between tissue types on the
basis of their behaviours in a magnetic field. Mammographic
density estimation is based on a single two-dimensional pro-
jection of the breast, in contrast to the three-dimensional MRI
image. Furthermore, each method uses a slightly different def-
inition of the extent of the breast, with implications for the
degree to which the axillary tail is included. It is hence not sur-
prising that the quantities estimated by the two methods are
not the same, despite being closely related. In the absence of
a practical, established gold-standard it is not possible to say
which is more accurate in any biological sense. However, by
examining the relationships between the density estimates and
various other factors, including breast cancer risk, we can
begin to evaluate their comparative usefulness.
Cumulus percent dense area and MRI percent dense volume
were both inversely associated with BMI, weight, hip, waist
Figure 3
Age-adjusted means and 95% confidence intervals for MRI absolute dense volume and Cumulus absolute dense volume by BRCA1/BRCA2  genetic status Age-adjusted means and 95% confidence intervals for MRI absolute dense volume and Cumulus absolute dense volume by BRCA1/BRCA2 
genetic status. P-values are for the comparisons with the group of women with uninformative BRCA1/2 genetic test results, as assessed by linear 
regression (P-values further adjusted for BMI and parity are given in parentheses). Arithmetic means are presented for the Cumulus measurement; 
geometric means are shown for the MRI measure (for which the regression analyses were based on log-transformed values). Box areas are propor-
tional to sample size.Available online http://breast-cancer-research.com/content/11/6/R80
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and chest circumferences, age over 45 years, with postmeno-
pausal status and with tamoxifen use, in line with previous
reports specific to Cumulus and other mammographic density
methods [13-18]. This confirms firstly that the usual accepted
determinants of breast density also apply in this high-risk pop-
ulation, and secondly that they apply similarly to MRI percent
dense volume.
We found carrying a BRCA1 mutation to be associated with
significantly lower mammogram-based density, both in terms
of absolute and percentage dense area, but the relationship
was less clear for the MRI percent dense area, and was not
true for MRI absolute dense volume. There was no evidence of
any relationship between BRCA2 mutation status and breast
density. Mitchell et al 2006 [2] found no relationship between
Cumulus percent dense area and BRCA1 or BRCA2 carrier
status in an analysis based on a slightly smaller set of women,
but with a higher proportion of mutation carriers and with con-
siderably more women who developed breast cancer (breast
cancer cases were not excluded at study recruitment). Specif-
ically, among the set of 176 BRCA1 mutation carriers ana-
lysed by Mitchell et al, 36% developed breast cancer,
compared with only 17% of our 94 BRCA1 carriers, hence it
is possible that their group of carriers were biased towards
women with denser breasts (and thus higher risk, if density
modifies breast cancer risk in mutation carriers in the same
way that it does in the general population). This would have
obscured any more general association between BRCA1
mutation status and low density. Conversely, the opposite may
well be true, in that we specifically excluded women who had
developed breast cancer prior to recruitment (mean age at
entry = 40 years). According to the same logic, this could have
biased our set of BRCA1 carriers towards those with a lower
than average density. The same would not necessarily have
been seen for BRCA2 carriers, in whom a greater proportion
would be expected to be asymptomatic at the age of entry
regardless of the presence or absence of potential modifiers
such as density. The observation of lower density in BRCA1
mutation carriers would seem to be at odds with a report that
only BRCA1/p53-deficient mice developed lateral branches
and alveoli without pregnancy [19]. To our knowledge, there
are no other reports that examine this question, although there
are several studies reporting textural differences between
BRCA1/2 carriers and non-carriers from a Chicago study [20-
23].
The chief goal of breast density estimation is for the study and
prediction of breast cancer risk. High breast density is well
Table 3
Breast cancer risk according to MRI percent dense volume, Cumulus and VA percent dense area (Medial-Lateral Oblique view)
No. women No. cancers No. pyears IRR - binary (95% CI) P-value IRR - trend (95% CI) P-value
Adjusted for age ≥ 45 years
MRI % dense volume 655 56 4,328 1.68 (0.97, 2.94) 0.066 1.17 (0.92, 1.49) 0.21
Cumulus MLO % dense area 607 42 4,109 1.12 (0.61, 2.05) 0.72 1.06 (0.81, 1.40) 0.66
VA MLO % dense area 599 42 4,060 1.61 (0.87, 2.98) 0.13 1.25 (0.96, 1.64) 0.098
Adjusted for age ≥ 45 years, tamoxifen use, BMI and parity
MRI % dense volume 503 40 3,381 1.32 (0.64, 2.73) 0.46 1.10 (0.79, 1.54) 0.56
Cumulus MLO % dense area 456 30 3,123 0.89 (0.39, 2.03) 0.78 0.92 (0.63, 1.35) 0.68
VA MLO % dense area 450 30 3,085 1.61 (0.71, 3.68) 0.26 1.22 (0.84, 1.76) 0.29
Adjusted for age ≥ 45 years and BRCA1/2 status/carrier probability
MRI % dense volume 619 53 4,083 2.04 (1.16, 3.59) 0.013 1.30 (1.01, 1.67) 0.039
Cumulus MLO % dense area 591 39 4,006 1.82 (0.96, 3.45) 0.065 1.26 (0.95, 1.68) 0.11
VA MLO % dense area 583 39 3,957 2.24 (1.18, 4.26) 0.014 1.47 (1.11, 1.96) 0.008
Adjusted for age ≥ 45 years, BRCA1/2 status/carrier probability, BMI and parity
MRI % dense volume 489 39 3,276 1.76 (0.82, 3.77) 0.15 1.26 (0.87, 1.81) 0.22
Cumulus MLO % dense area 450 29 3,078 1.43 (0.62, 3.32) 0.41 1.09 (0.73, 1.63) 0.66
VA MLO % dense area 444 29 3,040 1.84 (0.81, 4.19) 0.15 1.37 (0.94, 2.02) 0.11
BRCA1/2 carrier probabilities estimated using Boadicea for untested women and those with an uninformative test result.
Pyears = number of person-years in study and follow-up period
IRR - trend = incidence rate ratio, estimated assuming a linear trend in risk ratio between quartiles
IRR - binary = incidence rate ratio for the higher two quartiles versus the lower two quartiles
CI = confidence interval.Breast Cancer Research    Vol 11 No 6    Thompson et al.
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Table 4
Breast cancer risk according to MRI percent dense volume and Cumulus and visual assessment percent dense area (Medial-Lateral 
Oblique view), by BRCA1/BRCA2 genetic status
No. women No. cancers No. pyears IRR (95% CI) P-value 
(adjusted age)
IRR (95% CI) P-value 
(adjusted age, BMI & parity)
BRCA1 Carriers
MRI % dense volume 117 21 687 1.84 (0.77, 4.38) 0.17 1.02 (0.26, 4.05) 0.98
Cumulus MLO % dense area 94 16 579 2.72 (0.99, 7.48) 0.053 1.24 (0.35, 4.37) 0.74
VA MLO % dense area 94 16 579 4.03 (1.40, 11.6) 0.010 3.39 (0.94, 12.2) 0.062
BRCA2 Carriers
MRI % dense volume 69 18 385 2.06 (0.78, 5.45) 0.15 3.10 (0.77, 12.4) 0.11
Cumulus MLO % dense area 71 15 418 1.66 (0.60, 4.60) 0.33 10.4 (1.58, 68.0) 0.015
VA MLO % dense area 71 15 418 1.75 (0.62, 4.90) 0.29 3.70 (0.64, 21.2) 0.14
Non-carriers
MRI % dense volume 361 14 2,532 4.49 (1.16, 17.3) 0.030 2.54 (0.56, 11.6) 0.23
Cumulus MLO % dense area 332 7 2,367 1.13 (0.25, 5.17) 0.87 0.24 (0.04, 1.45) 0.12
VA MLO % dense area 327 7 2,336 1.45 (0.32, 6.66) 0.63 0.43 (0.08, 2.41) 0.34
The non-carrier group includes those who tested negative for a known BRCA1/2 family mutation as well as those in whom no mutation was
detected after a BRCA1/2 mutation screen, because of small numbers.
Pyears = number of person-years in study and follow-up period
IRR = incidence rate ratio for the upper two quartiles relative to the lower two quartiles (the trend test was not attempted due to the small 
numbers). CI = confidence intervals.
Table 5
Breast cancer risk according to MRI absolute dense volume and Cumulus and visual assessment absolute dense areas (Medial-
Lateral Oblique view)
No. women No. cancers No. pyears IRR - binary
(95% CI) P-value
IRR - trend
(95% CI) P-value
Adjusted for age ≥ 45 years
MRI dense volume 651 56 4,291 2.08 (1.20, 3.62) 0.009 1.33 (1.05, 1.70) 0.020
Cumulus MLO dense area 607 42 4,109 0.76 (0.41, 1.41) 0.39 0.96 (0.73, 1.25) 0.75
Adjusted for age ≥ 45 years, BMI and parity
MRI dense volume 499 40 3,345 1.87 (0.98, 3.56) 0.058 1.25 (0.94, 1.66) 0.13
Cumulus MLO dense area 456 30 3,123 0.64 (0.30, 1.36) 0.25 0.84 (0.60, 1.19) 0.33
Adjusted for age ≥ 45 years and BRCA1/2 status/carrier probability
MRI dense volume 615 53 4,046 2.31 (1.31, 4.07) 0.004 1.42 (1.11, 1.83) 0.006
Cumulus MLO dense area 591 39 4,006 1.19 (0.63, 2.26) 0.59 1.11 (0.82, 1.50) 0.52
Adjusted for age ≥ 45 years, BRCA1/2 status/carrier probability, BMI and parity
MRI dense volume 485 39 3,240 2.16 (1.12, 4.17) 0.021 1.35 (1.01, 1.80) 0.042
Cumulus MLO dense area 450 29 3,078 0.99 (0.46, 2.13) 0.99 0.95 (0.64, 1.41) 0.81
BRCA1/2 carrier probabilities estimated using Boadicea for untested women and those with an uninformative test result.
Pyears = number of person-years in study and follow-up period
IRR - trend = incidence rate ratio, estimated assuming a linear trend in risk ratio between quartiles
IRR - binary = incidence rate ratio for the higher two quartiles versus the lower two quartiles
CI = confidence interval.
established as one of the strongest known risk factors for
breast cancer, with clearer associations for quantitative meas-
ures of percent density (such as Cumulus) than for qualitative
measures [1]. However, this is the first study to evaluate the
relationship between MRI-measured density and breast can-
cer risk. Although the estimated rate ratios for all of the per-
centage density measures were in the direction of a positive
association, none achieved statistical significance after taking
into account the multiple testing. This is in contrast with previ-
ous findings both in the general population and specifically in
BRCA1/2 mutation carriers.Available online http://breast-cancer-research.com/content/11/6/R80
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Mitchell et al reported a breast cancer odds ratio of 2.29 (95%
CI 1.23 to 4.26) for a combined group of BRCA1/2 mutation
carriers, comparing women with percent density ≥ 50% with
those with density < 50%, but found the comparison to be
non-significant when densities between 25 to 50% were com-
pared with < 25% [2]. They reported no difference in effect
size between BRCA1 and BRCA2 carriers. Only 17% of the
women in our study had a Cumulus percent density ≥ 50% (as
opposed to 45% of the women in the Mitchell et al. study), giv-
ing us a 30% power to detect a difference of the same magni-
tude as that reported by Mitchell et al. This difference in the
distribution of densities between the studies may be due to dif-
ferences in ascertainment criteria, as discussed above, or may
simply reflect the use of different digitizers.
Our results also appear at first glance to be different from
those seen in the general population; a recent meta-analysis of
42 studies reported an almost five-fold increase in risk for the
densest category (≥ 75%) versus the least dense (< 5%) [1].
However, the same meta-analysis gave more modest relative
risks for less extreme comparisons (e.g. RR = 2.11, 95% CI
1.70 to 2.63 for 25% to 49% versus < 5%, a comparison for
which our power was just 14%, based on 21 cancers). Only
10 of our women had a Cumulus percent density ≥ 75%, and
our comparison of the upper and lower halves of the distribu-
tion was effectively a comparison of those with Cumulus per-
cent densities above or below 29%, and so it is likely that we
did not have the statistical power to detect the kind of the
effect size that would be realistic for this comparison, whilst
the small numbers of cancers precluded any comparison of
more extreme levels of density. We did however also test for
trends in risk across quartiles of the density distributions, but
found no additional significant results. The set of breast can-
cers comprises a mixture of incident and prevalent cases, but
the small numbers do not allow separate analyses of these
groups.
The MARIBS study was originally designed to have suitable
power to detect differences in sensitivity between MRI and
XRM breast screening [5], rather than for testing associations
between density and risk. While we were unable to detect any
significant associations between percent density and breast
cancer risk, it is important to note that the results for the MRI
percent dense volume were broadly similar to those for Cumu-
lus percent dense area (despite MRI density being available
for more women). Therefore, it seems unlikely that MRI percent
density will be a markedly better predictor of cancer risk than
the conventional quantitative mammographic density meas-
ures, but may prove useful in cases such as TP53 mutation
carriers for whom x-ray mammography is not considered safe.
We also examined the value of the craniocaudal view in our
data set in the light of a recent report that the predictive value
of visually-assessed mammographic percent density based on
a mediolateral oblique view alone was substantially improved
when combined with density estimates from the craniocaudal
view [24]. We found no improvement after averaging over both
views, although our study may be underpowered to detect
such an effect, especially since the craniocaudal image was
not available for all of our subjects.
Table 6
Breast cancer risk according to MRI absolute dense volume and Cumulus and visual assessment absolute dense areas (Medial-
Lateral Oblique view), by BRCA1/BRCA2 genetic status
No. women No. cancers No. pyears IRR (95% CI) P-value 
(adjusted age)
IRR (95% CI) P-value 
(adjusted age, BMI & parity)
BRCA1 Carriers
MRI dense volume 117 21 687 3.62 (1.32, 9.90) 0.012 3.10 (0.95, 10.1) 0.060
Cumulus MLO dense area 94 16 579 1.54 (0.58, 4.10) 0.39 1.27 (0.39, 4.11) 0.69
BRCA2 Carriers
MRI dense volume 69 18 385 3.06 (1.14, 8.19) 0.026 6.75 (1.80, 25.2) 0.005
Cumulus MLO dense area 71 15 418 1.03 (0.34, 3.10) 0.96 1.44 (0.38, 5.47) 0.59
Non-Carriers
MRI dense volume 357 14 2,495 1.27 (0.44, 3.65) 0.66 0.79 (0.24, 2.67) 0.71
Cumulus MLO dense area 332 7 2,367 1.14 (0.25, 5.11) 0.87 0.58 (0.11, 3.06) 0.52
The non-carrier group includes those who tested negative for a known BRCA1/2 family mutation as well as those in whom no mutation was 
detected after a BRCA1/2 mutation screen, because of the small numbers.
Pyears = number of person-years in study and follow-up period
IRR = incidence rate ratio, estimated for the upper two quartiles vs the lower two quartiles (the trend test was not attempted due to the small 
numbers)
CI = confidence intervalBreast Cancer Research    Vol 11 No 6    Thompson et al.
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Interestingly, the one density outcome for which we did see a
consistent association with breast cancer risk, even after
adjusting for genetic status, BMI and parity, was the absolute
MRI dense volume, a measure which has not been studied
before. There appeared to be an approximate doubling of risk
between the upper and lower halves of the distribution, rising
to an over three-fold increase in BRCA1 and BRCA2 carriers.
It is possible that this is a false positive result. If it is true, it is
curious that MRI dense volume showed almost no significant
associations with any of the tested anthropometric or hormo-
nal factors. However, given that breast cancer is believed to be
initiated in the stromal or epithelial cells, it is plausible that the
total quantity of target tissue is a more relevant predictor of
breast cancer risk than the proportional density. In this context
it is interesting that the absolute MRI breast volume was the
only density measure not found to be lower in BRCA1 muta-
tion carriers. While clearly related to percent dense volume,
absolute dense volume is not capturing the same information;
we found that 37% of women were in a different half of the per-
cent MRI dense volume distribution than the absolute dense
volume distribution, explaining why the results for the two
measures were so different. No such breast cancer associa-
tion was seen for the Cumulus absolute dense area, suggest-
ing that the differences between mammographic and MRI
density are more marked when not adjusted for total breast
area/volume, and that the three-dimensional MRI dense vol-
ume provides a better estimate of the amount of tissue at risk
of carcinogenesis. These findings are necessarily preliminary
and will need to be confirmed in further studies.
Conclusions
The MRIBview algorithm for the MRI-based estimation of the
volume of dense tissue in the breast provides a viable alterna-
tive to quantitative mammographic density estimation and may
be of particular value in women at high genetic risk of breast
cancer for whom MRI breast screening is already recom-
mended. Although the nature of the available dataset limited
our power to detect associations between density and breast
cancer risk, MRI percent dense volume did not appear to per-
form markedly differently from Cumulus percent dense area.
However, the association between absolute MRI dense vol-
ume and breast cancer risk is a novel, and potentially important
finding that requires replication in a specifically designed
case-control study.
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